OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development
Wafa Bouleftour, Paul Sargos, Nicolas Magné
Current Oncology Reports (2023) Vol. 25, Iss. 3, pp. 181-188
Closed Access | Times Cited: 9
Wafa Bouleftour, Paul Sargos, Nicolas Magné
Current Oncology Reports (2023) Vol. 25, Iss. 3, pp. 181-188
Closed Access | Times Cited: 9
Showing 9 citing articles:
Therapeutic prospects of nectin-4 in cancer: applications and value
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 9
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 9
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy
Deepa Rajagopal, Elliot MacLeod, Diana Corogeanu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 13
Open Access | Times Cited: 4
Deepa Rajagopal, Elliot MacLeod, Diana Corogeanu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 13
Open Access | Times Cited: 4
High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy
Zhuo Xing, Tiejun Yang, Xurui Li, et al.
Cell Reports (2025) Vol. 44, Iss. 4, pp. 115545-115545
Open Access
Zhuo Xing, Tiejun Yang, Xurui Li, et al.
Cell Reports (2025) Vol. 44, Iss. 4, pp. 115545-115545
Open Access
Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2
Matej Maršić, Nives Jonjić, Maja Gligora Marković, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 5, pp. 296-296
Open Access
Matej Maršić, Nives Jonjić, Maja Gligora Marković, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 5, pp. 296-296
Open Access
Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database
Mingming Yu, Li‐Jun Zhou, Mengda Cao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Mingming Yu, Li‐Jun Zhou, Mengda Cao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
A cutting-edge 68Ga-labeled bicyclic peptide PET molecular probe for noninvasive assessment of Nectin4 expression
Shushan Ge, Tongtong Jia, Jinyu Shi, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107745-107745
Closed Access
Shushan Ge, Tongtong Jia, Jinyu Shi, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107745-107745
Closed Access
A new perspective in the research of antibody drug conjugate
Qiao Li, Mingxia Jiang, Binghe Xu
The Innovation Medicine (2023) Vol. 1, Iss. 2, pp. 100018-100018
Open Access
Qiao Li, Mingxia Jiang, Binghe Xu
The Innovation Medicine (2023) Vol. 1, Iss. 2, pp. 100018-100018
Open Access
Nectin-3 and Nectin-4: potential prognostic biomarkers for therapeutic targeting of cancer
Aihong Yang, Yan Ge, Panpan Yang, et al.
Tropical Journal of Pharmaceutical Research (2023) Vol. 22, Iss. 10, pp. 2235-2241
Open Access
Aihong Yang, Yan Ge, Panpan Yang, et al.
Tropical Journal of Pharmaceutical Research (2023) Vol. 22, Iss. 10, pp. 2235-2241
Open Access
